Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, has expanded Kite's R&D leadership team with the appointments of William Y. Go, M.D., Ph.D., as senior director, Clinical Development, and Jeff Aycock as senior director, Clinical Operations.
Previously, Go held senior positions of increasing responsibility at Amgen, most recently as U.S. medical lead for Vectibix, medical director in Global Development. He led the U.S. Vectibix Development team to a successful label expansion of this product and also was clinical lead for the Amgen's immunotherapy strategy team.
Aycock brings more than 17 years of drug development experience investigating a broad range of oncology drug candidates in both the pediatric and adult settings. Previously, Aycock held roles of increasing responsibility over 13 years at Amgen. He was a key leader within the Kepivance and Nplate development programs that resulted in Biological License Application (BLA) submissions and marketing authorizations for both drug candidates. In his most recent position at Amgen as director, Oncology Study management & U.S. regional lead, Aycock oversaw five oncology programs, ensuring alignment between the global strategies, study design and execution of phase II-IV clinical trials. He began his career at Parexel and Pfizer.